Deregulation of protein and lipid kinases of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival. Protein kinase and lipid kinases represent, therefore, an important target for the pharmaceutical industry. In fact, approximately one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases. To date 27 kinase inhibitors that have been approved, which, with few exceptions, are mainly for oncological indications and are directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped. Despite of these successes the major challenges in kinase drug discovery the development of kinase inhibitors with outstanding selectivity, the identification and validation of driver kinase(s) in diseases and the emerging resistance to the inhibition of key target kinases remain major challenges. This review will provide an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors and novel avenues for the generation of second generation kinase inhibitors to treat cancers.
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56 lymphoma cell lines. We observed anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure. PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity. Both the single agent and the combination data were validated in xenograft models. The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.
1 July 2013 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics